Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$66.44M+6.4%-$73.2M-33.7%-$77.84M-63.3%-$73.37M-49.9%-$70.96M-55.9%
$1.86M+59.0%$1.57M+36.7%$1.27M+3.4%$1.22M+1.3%$1.17M-3.3%
$18.99M+142%$16.38M+157%$13.63M+118%$11.13M+95.8%$7.83M+39.8%
-$54.78M+2.4%-$50.93M-5.5%-$56.58M-34.4%-$57.46M-41.5%-$56.1M-53.8%
$6.34M+90.9%$5.3M+56.0%$3.96M+34.8%$4.59M+312%$3.32M+370%
-$190.24M-326%
$4.38M-98.4%$214.87M+286%$270.71M+1,029%$266.88M+429%$266.73M+252%
$20.38M+483%
-$61.12M-2.9%-$56.22M-8.8%-$60.53M-34.4%-$62.06M-48.8%-$59.43M-59.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Beta Bionics, Inc. Common Stock generate?
Beta Bionics, Inc. Common Stock (BBNX) generated -$54.8M in operating cash flow over the trailing twelve months.
What is Beta Bionics, Inc. Common Stock's free cash flow?
After $6.3M of capital expenditures, Beta Bionics, Inc. Common Stock's free cash flow was -$61.1M over the trailing twelve months, down 2.9% year over year.
Where does Beta Bionics, Inc. Common Stock's cash flow data come from?
Every line is extracted from Beta Bionics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.